Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer

Kochi University

Status: Completed

Conditions: Pancreatic Cancer Resectable

Treatments: Drug: gemcitabine

Study type: Observational

Funder types: Other

Identifiers

NCT06809374

iON study

Details and patient eligibility

About

Investigating the Optimal Duration of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer to Determine the True Surgical Indication.

Enrollment: 100 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• radiologically resectable pancreatic cancer patients

Exclusion criteria

• a body weight loss of greater than 10% during the six months prior to surgery, the presence of distant metastases, or seriously impaired function of vital organs due to respiratory, renal, or heart disease